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Background: Pneumococcal diseases in children under five years are common and preventable. In Colombia there
are two pneumococcal conjugate vaccines (PCV) that have proved clinical efficacy. The aim was to estimate the
cost-effectiveness of 13-valent PCV (PCV13) and 10-valent PCV (PCV10) in terms of prevention of Invasive Pneumococcal
Diseases (IPD), radiologically-confirmed pneumonia, and their related mortality, as well as, acute otitis media (AOM) in a
cohort of newborns in Colombia.
Methods: We developed an analytical decision tree model with national data including the distribution of
pneumococcal serotypes in Colombia between 2009 and 2013. A simulation of vaccination of 90% of newborns in
Colombia took place with a time horizon of 5 years. The analysis was done from the Colombian health system
perspective. Vaccines efficacy parameters were measured as life-years gained (LYG) and avoided morbidity by
pneumococcal diseases; they were determined by a systematic review of literature. A health insurance company provided
the costs. A probabilistic and a univariate sensitivity analysis for epidemiological, efficacy and cost parameters were done.
Results: After 5 years projection, PCV13 would prevent 437 deaths due to pneumococcal infections versus 321 that
would be prevented by PCV10, compared to no vaccination. PCV13 would generate 25 396 LYG, and PCV10 would
generate 18 708 LYG. Medical costs avoided would be US$ 19 479 395 for PCV13 and US$ 13 703 271 for PCV10.
Compared to no vaccination, PCV13 and PCV10 were cost-effective, with an incremental cost-effectiveness ratio (ICER) of
US$ 489.26 and US$ 813.41 per additional LYG, respectively; besides, PCV13 was dominant over PCV10 due to lower costs
and better outcomes.
Conclusion: PCV13 is a cost-saving strategy compared with PCV10, as part of a universal coverage vaccination program
in Colombian children under one year. PCV13 is expected to lead to a greater decrement in infant mortality from
pneumococcal diseases, and a higher cost saving by preventing more pneumococcal diseases compared with PCV10 in a
5 years projection.
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The diseases produced by Streptococcus Pneumoniae (SP),
such as pneumonia, sepsis (including bacteremia), meningi-
tis and acute otitis media (AOM) are a severe public health
problem. Annually, 2 million children die worldwide due to
pneumonia, which is more than those due to AIDS, malaria
and measles together [1]. In order to reduce the mortality
rate in children younger than 5 years by two thirds, one of
the Millennium Development Goals (MDG) [2] included
strategies as pneumococcal vaccination. [3].
In 2000 was introduced the first pneumococcal conju-
gated vaccine. This vaccine was composed of purified cap-
sular polysaccharides of seven pneumococcus serotypes (4,
6B, 9 V, 14, 18C, 19 F and 23 F) conjugated to a diphteria
protein (CRM197), and demonstrated its clinical efficacy
and effectiveness (PCV-7) [4-6]. A health economics ana-
lysis concluded that PCV7 would prevent 678,000 AOM
cases and 175,000 pneumonia cases due to SP by year in
Latin America and the Caribbean region [7]. In Uruguay,
PCV7 was found highly cost-effective and recommendable
for countries with a similar distribution of serotypes [8].
In 2010 it was launched, a 10-valent conjugate vaccine
(PCV-10), that add the three serotypes 1, 5 and 7 F.
Eight of the ten serotypes in PCV10 are conjugated to
the D protein of non typeable Haemophilus influenza, of
the remaining two, one to tetanus toxoid and one to
diphtheria toxoid. Later, the 13-valent pneumococcal
conjugate vaccine (PCV13) was launched with the three
additional serotypes 3, 6A and 19A. All 13 serotypes in
PCV13 are conjugated to CRM197, the same protein car-
rier used for PCV7.
Currently, in Colombia there are two available tech-
nologies to prevent pneumococcal diseases in children
younger than 5 years, PCV10 and PCV13. Due to the
difference in terms of the effectiveness and costs of the
vaccines, it is necessary to estimate the cost-effectiveness
of both strategies in order to allow an informed decision
taking. Our objective is to estimate the cost-effectiveness
ratio between PCV13 and PCV10 as part of an infant
vaccination program, considering the current pneumo-
coccal serotypes distribution in Colombia.Methods
An analytical decision tree model was constructed (Figure 1)
with local data on the prevalence of Invasive Pneumococcal
Disease (IPD) (meningitis and sepsis, including bacteremia),
pneumococcal AOM and radiologically-confirmed pneu-
monia. The model was developed by the authors and simu-
lates a cohort of newborns in Colombia. The model
assumed that at the beginning, individuals would be vacci-
nated with PCV13 or PCV10 or would not be vaccinated.
Mortality rates from IPD and pneumonia were considered
to calculate deaths avoided. Costs of medical treatmentswere calculated based on the site of healthcare, it means,
inpatient or outpatient.
To determine epidemiologic distribution of SP serotypes
found in children younger than 5 years in Colombia be-
tween 2009 and 2013, we used the data of Regional Vaccine
System (SIREVA II; by their acronym in Spanish), which re-
ports serotypes of all isolates made in Colombia by IPD. A
systematic review was done, in order to determine the effi-
cacy of both vaccines, adjusted to the distribution of
pneumococcal serotypes. This research does not involve
any human subject, and secondary sources of information
such as scientific papers and bills payment were used.Model
The cohort to evaluate morbidity children was born in
Colombia in 2012; with a 5 follow up years. In order to
calculate the life-years gained (LYG), the life expectancy
during the period 2010-2015 for both sexes was assumed
[9]. The reason for using children born in 2012 as the
cohort group rather than the population projections
made by the National Administrative Department of Sta-
tistics (DANE; by their acronym in Spanish) for later
years; is that the results of those projections are 20%
below of the real-life data.
The international health agencies and the local regulatory
agency (INVIMA for Colombia) have approved the use of
both vaccines: PCV10 and PCV13, based on comparison of
immunologic response to PCV7 to common serotypes.
Thus, PCV7 is the basis for the clinical efficacy and is the
support to approve other conjugated vaccines [10].
Since PCV13 and PCV10 have regulatory approval to
prevent pneumococcal diseases caused by the serotypes
included in the vaccines, the probabilities of becoming
ill by these serotypes were adjusted according to the SIR-
EVA II, which reports the serotypes that cause IPD and
are isolated in Colombia [11].
In order to depict the risk for clinical outcomes, pneumo-
coccal sepsis, pneumococcal meningitis, radiologically-
confirmed pneumonia and pneumococcal AOM, a decision
analytical tree model was used [4-8]. To estimate
avoided deaths, the probability of death from pneumonia,
meningitis and sepsis was considered. A discount rate of
3% for costs and effects was applied, according to the rec-
ommendation of the World Health Organization (WHO)
[12]. The analysis was done from the Colombian health
system perspective.
Three alternatives were considered: not vaccination,
vaccination with PCV10 or vaccination with PCV13.
The direct efficacy of the vaccines was considered during
the first 5 years of life. The cost-effectiveness analysis
was performed among the three alternatives in terms of
each disease related morbidity cases and deaths, as well
as, life-years gained (LYG).





























Figure 1 Decision tree for the cost-effectiveness analysis on vaccinating with PCV13, PCV10 or not vaccinating in a cohort of newborns
in Colombia.
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In order to determine the likelihood of IPD, the inci-
dence was calculated using a local study performed in
Colombian population [13]. The likelihood of developing
radiologically-confirmed pneumonia was calculated [14]
based on population indicators of pneumonia like the
discharge diagnosis in children younger than 5 years
in Medellin during 2009 [15]. This was adjusted ac-
cording to the proportion of children with a clinicaldiagnosis of pneumonia that could be confirmed
radiologically [13].
The incidence of AOM was estimated only for
pneumococcal AOM according with the indications ap-
proved by the INVIMA. The population indicators of
AOM used were the discharge diagnosis from the
emergency room or outpatient visits in children youn-
ger than 5 years in Medellin during 2009 [15]. This was
adjusted according to the proportion of children with a
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the confirmed etiologic agent [17].
The probability of mortality due to IPD was 37% and
to pneumonia 3%, it was determined by assuming the
values reported on a cost-effectiveness study of PCV7
performed in Colombian children during 2010 [18]. Vac-
cination coverage of 90% was assumed, in line with the
assumptions by other authors [18]. A herd effect of 42%
was assumed based on the decline rate of IPD in infants
0 to 60 days old that were not vaccinated with PCV7
who lived in the same regions of the vaccinated children
[20]. Thus, if 10% of children are not vaccinated, the
protecting effect of the vaccine would also benefit 4.2%
of this 10% (Table 1).
Measurement of effectiveness
Vaccines effectiveness was assessed by a systematic re-
view The following databases were used: EBSCO Host,
EMBASE, OVID, PLoS, PubMed, Science Direct,
Springer, Wiley InterScience, Wolters Kluwer Health
and Randomized Controlled Essays were considered.
The MeSH terms used in the search, in different com-
binations, were: pneumococcal vaccines, streptococcus
pneumonia, sepsis, pneumococcal meningitis, pneu-
monia, and otitis media.
The repeated references were removed, as well as
those with polysaccharide vaccines; with adults with im-
munodeficiencies; with senior adults; with a shorter than
six months follow up period and those that only evaluated
immunogenicity without considering clinical results.
PCV7 was the first conjugated vaccine with published
efficacy studies for IPD; PCV10 and PCV13 were approved
based on immunogenicity comparisons with PCV7. One
RCT determined the efficacy of PCV7 for preventing men-
ingitis and sepsis in children under 5 years [5]. The PCV13
efficacy for radiologically-confirmed pneumonia was taken
from a study made with PCV7 in children under than
5 years [21].
The PCV10 efficacy for radiologically-confirmed pneu-
monia and IPD was taken from the COMPAS study, a mul-
ticenter study in which Colombia participated [22].
The effectiveness of vaccines against AOM, were ad-
justed according to the prevalence of the pneumococcus
serotypes in Colombia. Based on their clinical effective-
ness, this was adjusted according to the circulating sero-
types in the country and that are contained in each
vaccine. We did that adjustment because a vaccine could
have a high effectiveness but against serotypes with a
low prevalence in our country.
In the case of PCV13, we took PCV7 efficacy to prevent
pneumococcal AOM (83% (IC 95%: 75% - 91%)) [23]
caused by serotypes contained in PCV7. To determine the
efficacy of PCV10 to prevent pneumococcal AOM, we as-
sumed it reported on a RCT that evaluated an 11-valentprecursor to PCV10 (52.6% (IC 95%: 35.0% - 65.5%)) [16].
Based on the reports by SIREVAII between 2009 and 2013,
PCV10 covers 61.6% and PCV13 covers 82.0% of pneumo-
coccus serotypes causing invasive disease in Colombia in
children under than 5 years [11]. It means, PCV13 efficacy
was adjusted by 82.0% and PCV10 efficacy was adjusted by
61.6% (Table 1).
Economical parameters
The direct costs include the costs of the PCV10 (Synflorix®)
and PCV13 (Prevenar 13®) vaccines and the application of
three doses. The values used are the ones recom-
mended by the Pan American Health Organization for
2014 [24]. Medical costs associated with the treatment
of disease were assumed to be a lower value to pay for
each case prevented (Table 1).
The database of a national health insurance company
which has more than 2 million members (which ensures
the representativeness of the population), was used to
determine the costs for treating sepsis, meningitis and
pneumonia in children younger than 5 years in Colombia.
The costs were determined based on the value paid by the
health insurance companies to the hospitals and it com-
prises all of the services offered during the hospitalization
including hospital visits, diagnostic aids, antibiotic treat-
ments and other necessary services used for the recovery
of the patient until discharge. The rates for all these ser-
vices are based on a government reimbursement manual
for national application. In 2013, this health insurance
company reported a total of 72 children younger than
5 years with sepsis, 36 with meningitis and 541 with pneu-
monia. These values were adjusted with the Consumer’s
Price Index reported by the DANE for 2013: 1.94% [25].
An exchange rate of COP 1 959 was assumed for the cal-
culation in dollars, since it was the average exchange rate
for the first six months of 2014.
To calculate the cost of care for an episode of AOM,
two clinical guidelines [26,27] that propose the same
antibiotic treatment (amoxicillin 90 mg/kg/day) were
considered. The cost of a 90 ml acetaminophen bottle was
added to this treatment regimen as well as the cost of two
outpatient visits, based on the values of the national tariff
manual updated to 2014 [28] (Table 2).
It was considered that an alternative is cost-effective if
the cost per additional unit of effectiveness (LYG) is less
than 3 Colombian GDP per capita (US$ 24,075 for
2013), and highly cost-effective if less than 1 Colombian
GDP per capita (US$ 8 025 for 2013) [29].
Incremental cost-effectiveness analysis
When a technology is more cost-effective than other but
at the same time is costlier, it is necessary an economic
decision criteria. The question in this case would be how
much additional costs have to be paid for the additional
Table 1 Demographic and epidemiologic parameters of the probability of developing pneumococcal disease and the
efficacy of PCV13 and PCV10 and cost of care in Colombian children younger than 5 years, 2014
Parameters Mean value Data distribution Reference
Demographic
Newborns in 2012 676 835 Does not vary [19]
Life expectancy 73,78 Does not vary [9]
Discount rate 3% 2% - 5% [13]
Epidemiologic
Pneumococcal sepsis probability 0,000184 Beta [13]
Pneumococcal meningitis probability 0,000037 Beta [13]
Radiographically confirmed pneumonia probability (a) 0,007441 Beta [13,15]
Pneumococcal AOM probability (b) 0,031171 Beta [15,17]
PID mortality (meningitis, sepsis) 37% Beta [18]
Pneumonia mortality 3% Beta [18]
Vaccination coverage 90% Beta Assumption
Herd effect 42% [20]
Parameter Mean value Range Data distribution References
Inferior limit Superior limit
Efficacy of intervention
Meningitis, sepsis PCV10 65,0% 11,1% 86,2% Beta [22]
Radiographically confirmed pneumonia PCV10 22,4% 5,7% 36,1% Beta [22]
AOM due to S. pneumoniae PCV10 (c) 32,4% 21,6% 40,4% Beta [11,16]
Meningitis, sepsis PCV13 89,1% 73,7% 95,6% Beta [5]
Radiographically confirmed pneumonia PCV13 30,3% 10,7% 45,7% Beta [21]
AOM due to S. pneumoniae PCV13 (d) 68,1% 61,5% 74,6% Beta [11,23]
Vaccine costs
Cost of PCV10 $ 14,12 $ 12,71 $ 15,53 Gama [24]
Cost of PCV13 $ 15,68 $ 14,11 $ 17,25 Gama [24]
Administration cost (per dose) $ 1,00 $ 0,9 $ 1,10 Gama Assumption
Cost of sepsis $ 8 192 $292 $ 104 535 Gama Health insurance company
Cost of meningitis $11 595 $ 1 165 $ 54 891 Gama Health insurance company
Cost of pneumonia $ 1 854 $ 306 $ 40 812 Gama Health insurance company
Cost of AOM $ 40 $ 36 $ 44 Gama [26,27]
a. Incidence of pneumonia in Medellin in 2009, adjusted to the proportion of pneumonia cases confirmed radiographically (Benavides et al [13]).
b. Incidence of AOM in Medellin in 2009, adjusted to the proportion of AOM cases due to pneumococcus (Sierra et al [17]).
c. Clinical efficacy of PCV11 for preventing AOM due to S. pneumoniae, adjusted according to the proportional frequency of serotypes circulating in Colombia
between 2009 and 2012, contained in PCV10.
d. Clinical efficacy of PCV7 for preventing AOM due to S. pneumoniae, adjusted according to the proportional frequency of serotypes circulating in Colombia
between 2009 and 2012, contained in PCV13.
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Effectiveness Ratio (ICER). In other words, what was the
incremental cost for PCV13 compared to the PCV10
and not vaccination related to the corresponding incre-
mental effectiveness?
Sensitivity analysis
In order to assess the robustness of the model, as well as
the sensitivity of the ICER to the parameters of the mainvariables, univariate and probabilistic sensitivity analysis
were done. For the first case, the extreme values of the
ranges were used to test the ICER results. For the prob-
abilistic sensitivity analysis, a one thousand iterations
Montecarlo simulation was performed. Beta distribution
was used for clinical parameters and gamma distribution
for the avoided medical costs and vaccine costs. The beta
and gamma parameters were calculated with the respect-
ively means and standard deviations of each variable.
Table 2 LYG, Total costs and ICER for PCV13, PCV10 and





Total discounted LYG 0 18 708 25 396
Discounted medical costs
avoided
0 $ - 13 703 271 $ - 19 479 395
Vaccine costs* 0 $ 28 920 564 $ 31 904 432
Total costs 0 $ 15 217 293 $ 12 425 037
C/E Prevented cases
(per additional LYG)
$ 813.41 $ 489.26
Incremental analysis
ICER No Vaccine vs. PCV10 $ 813.41
ICER PCV10 vs. PCV13 $ - 417.53
*Included administration costs.
LYG: Life Years Gained.
C/E: Cost-effectiveness ratio.
Table 3 Prevented cases of sepsis, meningitis,
pneumococcal AOM and radiographically confirmed
pneumonia; as well as prevented deaths per year and life
years gained, when applying PCV13 and PCV10 in
Colombian children younger than 5 years, 2014
Parameter PCV13 PCV10
Prevented cases
Pneumococcal sepsis 510 372
Pneumococcal meningitis 103 75
RX confirmed pneumonia 7 011 5 183
Pneumococcal AOM 66 005 31 401
Prevented deaths
Pneumococcal sepsis 189 138
Pneumococcal meningitis 38 28
RX confirmed pneumonia 210 155
All causes 437 321
Life years gained
Pneumococcal sepsis 5 565 4 059
Pneumococcal meningitis 1 119 816
RX confirmed pneumonia 18 712 13 832
All causes 25 396 18 708
Ordóñez and Orozco Cost Effectiveness and Resource Allocation  (2015) 13:6 Page 6 of 12Acceptability curves and cost-effectiveness plane was in-




After 5 years follow up projection, compared to no vaccin-
ation, PCV13 would prevent 66 005 pneumococcal AOM
cases and 437 deaths due to pneumococcal infections and
PCV10 would prevent 31 401 pneumococcal AOM cases
and 321 deaths due to pneumococcal infections. In the
same way, PCV13 would generate 25 396 LYG and PCV10
would generate 18 708 LYG (Table 3).
Costs
Although the cost to vaccinate 90% of children was
higher for PCV13 compared to PCV 10 (US$ 31 904 432
versus US$ 28 920 564), this price is compensated by
the greater savings obtained by the avoided cases with
PCV13 compared to PCV10. Medical costs avoided were
US$ 19 479 395 for PCV13 and US$ 13 703 271 for
PCV10.
Cost-effectiveness of the pneumococcal conjugate
vaccines
PCV13 showed a better cost-effectiveness ratio for the
cases of meningitis, sepsis, radiologically-confirmed pneu-
monia and AOM prevented. Cost-effectiveness ratio to
prevent pneumococcal AOM cases was US$ 446.15 with
PCV13 and US$ 883.79 with PCV10. Compared to no
vaccination, the ICER of PCV13 US$ 489.26 per LYG,
while the ICER of PCV10 was US$ 813.44 per LYG. With
a greater effectiveness and lower costs, PCV13 was dom-
inant to PCV10 (Table 2).Univariate sensitivity analysis
For the univariate sensitivity analysis, the high and low
ranges of the discount rate, vaccines’ costs, treatments
costs and effectiveness of the vaccines were tested in the
univariate analysis. It allows to observe how sensible was
the ICERs to this changes. PCV13 was dominant over
PCV10 in ten of 12 variations (Table 4 and Figure 2).
Therefore, the ICER result in the univariate sensitivity
analysis shows a very robust model.
Probabilistic sensitivity analysis
The probabilistic sensitivity analysis showed the robustness
of results of the model. Most of the simulations of PCV10
and PCV13 overlapped each other, and were located in the
NE and SE quadrants relative to not vaccinating, support-
ing that both options were more effective than not vaccin-
ating. PCV13 offered more LYG than PCV10 and a lesser
cost. In 81% of the 1 000 simulations made by the model,
PCV13 is cost-effective compared to PCV10 (Figure 3).
Acceptability curves
The acceptability curves allow to know what is the likeli-
hood for a strategy to be chosen, compared with the an-
other one. For a willingness to pay of 1 GDP per Capita for
Colombia, PCV13 has a probability of 78% to be chosen,
meaning this is strategy is highly cost-effective. In the same
way, for a willingness to pay of 3 GDP, PCV13 has a prob-
ability of 81% to be chosen and PCV10 has a probability of
19% (Figure 4).
Table 4 Univariate sensitivity analysis of ICER results of PCV13 vs PCV10 vs no vaccination in Colombian children
younger than 5 years, 2014
Base case Lowest value Highest value













Discount rate 3% 813,41 - 417,53 2% 612,22 - 338,43 5% 1.288,37 - 572,40
Vaccine costs (US$)
PCV10 45,36 813,41 -417,53 41,12 669,04 - 13,68 49,60 957,77 - 821,39
PCV13 50,04 813,41 - 417,53 45,34 813,41 - 866,01 54,74 813,41 - 30,94
Medical costs (US$)
Avoided cases Mean values 813,41 - 417,53 Mean values 1.401,61 - 185,47 Mean values 11.082,66 - 12.268,58
PCV10 effectiveness
Sepsis 0,6500 813,41 -417,53 0,1110 5.804,26 - 609,93 0,8620 288,94 - 1.223,03*
Meningitis 0,6500 0,1110 0,8620
Pneumonia 0,2240 0,0570 0,3610
OMA 0,3240 0,2160 0,4040
PCV 13 effectiveness
Sepsis 0,8910 813,41 - 417,53 0,7370 813,41 - 923,48* 0,9630 813,41 - 568,52
Meningitis 0,8910 0,7370 0,9630
Pneumonia 0,3030 0,1070 0,4468
OMA 0,6810 0,6150 0,7944
PCV13: 13-valent pneumococcal conjugate vaccine.
PCV10: 10-valent pneumococcal conjugate vaccine.
NV: no vaccination.
*In these two cases, PCV10 is dominant.
(14,000.00)(12,000.00)(10,000.00) (8,000.00) (6,000.00) (4,000.00) (2,000.00) 0.00 2,000.00
Discount rate (0,02-0,05)
PCV 10  cost (41,12-49,6)
PCV 13 cost  (45,34-54,74)
PCV 13  effectiveness (0,737-0,963)




Figure 2 Tornado diagram of PCV13 vs. PCV10 to prevent pneumococcal diseases in a cohort of Colombian children, 2014.



























Figure 3 Probabilistic cost-effectiveness plane in which the LYG are plotted versus the costs for PCV13 and PCV10 in a cohort of
Colombian newborns, 2014.
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This cost-effectiveness analysis has identified the clinical
and economical results of PCV13 and PCV10. From the
Colombian health system perspective both strategies are
superior to no vaccination in terms of prevented cases,
ICER, LYG and prevented deaths.
PCV13 presented more benefits in regards to prevented
cases and deaths due to IPD, radiologically-confirmed
pneumonia and AOM. PCV13 is the dominant option overPCV10 since it avoids more deaths, more LYG are obtained
and fewer resources are consumed due to greater reduction
in disease.
There is no doubt that vaccination with pneumococcal
vaccines from 2000 has been a positive impact on public
health to prevent pneumococcal diseases, particularly
mortality related with S. pneumoniae. Our main contri-
bution to this discussion is to generate valid information


















3 GDP per Capita
Figure 4 Cost-Effectiveness Acceptability curves of PCV13 vs. PCV10 vs. no vaccine to prevent pneumococcal diseases in a cohort of
Colombian children, 2014.
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carry out an immunization program with pneumococcal
vaccines in our country.
On 2007 PCV7 was included in the Colombian Plan of
Immunization; initially for high risk population and later
for low weight newborns and the ten departments with
the highest mortality rates [30]. Since 2010, was imple-
mented the universal vaccination with PCV13 based on
the additional coverage of six serotypes increasing the
coverage up to approximately 60% of the national territory.
In September 2011 the Colombian Plan of Immunization
replaced the PCV13 with PCV10. This change was after the
publication of a cost-effectiveness study that evaluated
PCV7, PCV10 and PCV13 [19]. There was a model that as-
sumed that PCV10 would have an excess impact on pre-
venting AOM due to all causes, even though PCV13 would
prevent more cases of pneumonia, IPD and deaths [18].
The main differences of this model with the latest
cost-effectiveness study published on the subject in the
country [18] are (1) the assumption that PCV10 is ef-
fective against non-typeable H. influenza, (2) the AOM
prevalence parameter which was not adjusted specifically
for pneumococcus, (3) the medical costs source is not
local and (4) the time periods analyzed in both studies
were different (2007-2009 vs. 2009-2013).
The higher number of IPD and pneumonia cases
avoided with PCV13 shown in both studies was based
mainly on the better coverage of the circulating sero-
types in Colombia by PCV13; serotype coverage is
33% higher than the coverage by PCV10: 82.0% vs.
61.6% [11].
Although the cost of every dose of PCV13 is US$ 1.56
higher than PCV10, the largest IPD and AOM cases
avoided with PCV13 allows the latter to be a dominantstrategy, because the savings generated by direct costs of
treatment of cases avoided are greater than the costs dif-
ference in an immunization program between both of
them strategies. Even though the analysis perspective
was from a Colombian health system, it could be in-
ferred that from a societal perspective the results would
be similar, because issues related with both of patients
and caregivers, such as travel times to medical appoint-
ments or time to care sick children, will be greater in
the strategy that avoided fewer IPD and AOM cases.
The results of this research coincide with another ten
cost-effectiveness analysis on PCV13 performed in dif-
ferent countries [31-40]. All these conclude that PCV13
prevents more cases and more deaths due to pneumo-
coccal diseases than PCV10 and thus is a better alterna-
tive in terms of costs compared to PCV10. Strutton et al
[31] conclude that a pediatric national immunization
program with PCV13 would eliminate 31.7% of IPD in
Germany, 46.4% in Greece, and 33.8% in the Netherlands,
and it was a cost saving strategy, compared with PCV7 and
PCV10. Earnshaw et al point out that an immunization
program with PCV13 is a cost-saving strategy in Canada
because it provides substantial public health and economic
benefits versus to PCV10 [33].
Furthermore, Newall et al assert that the high propor-
tion of current IPD caused by serotype 19A (included in
PCV13 but not in PCV10) may be an overriding factor
in the design of vaccination policies in Australia [32]. In
the same way, isolates in Colombia of serotype 19A have
increased seven times, and serotype 3 have increased
four times, between 2009 and 2013 compared with the
period between 1994 and 2008 [11].
In the same way, all these health economic evaluations
[31-40] used analytical decision tree models as the best
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history of pneumococcal diseases and PCV, because these
are acute diseases and their probability of recurring events
is low. In fact, the effectiveness of both vaccines used in this
model is calculated only against the serotypes included in
each vaccine and we did not considered cross immunogen-
icity. Although there is the likelihood to suffer disabilities in
patients with meningitis, i.e. deafness, our main outcomes
were mortality and life years gained, since this is a cost-
effectiveness analysis, not a cost-utility analysis.
In Latin America there are two important studies with
similar results, one in Mexico and another one in
Uruguay. The first one concludes that immunization with
PCV7, PCV10 or PCV13 would be cost-saving interven-
tions, however, health outcomes and savings of the strat-
egy with PCV13 are greater than those estimated for
PCV7 and PCV10 [37]. The later concluded that there
was a significant decline on incidence of hospitalizations
for consolidated pneumonia in children younger than
2 years of age, related with a vaccination schedule of 2 + 1
with PCV13 [40].
Five research studies have concluded that PCV13 avoids
more deaths due to pneumococcal diseases than PCV10,
but no more cases of overall disease [18,37,41-43]. The re-
sults of these differ from the above studies because they as-
sume that PCV10 is effective in preventing AOM due to S.
pneumoniae and also to non-typeable H. Influenzae. Such
cost-effectiveness analysis based this assumption on the
study made on PCV11 by Prymula [16]. However, this
study did not use PCV10, used a 3 + 1 immunization
schedule, and represented only a subset of the most severe
cases of AOM with a higher proportion of bacterial cases.
A recent study showed PCV10 to have considerably less
impact on all cause AOM in a controlled environment par-
ticularly when used in a 2 + 1 schedule [44]. By contrast,
PCV13 is similarly effective in 3-dose and 4-dose schedules
versus AOM [45]. In addition, a recent randomized trial of
NP carriage of NTHi comparing PCV7 to PCV10 found no
effect of PCV10 in reducing NTHi carriage. Therefore, it is
unlikely that any proposed non-pneumococcal benefits will
be realized with PCV10 [46]. Furthermore, the regulatory
approval issued by the INVIMA and the European Medi-
cines Agency points out that PCV10 is indicated for pre-
venting diseases produced by the serotypes included in the
pneumococcal vaccine [47].
Results from the Clinical Otitis Media and Pneumonia
Study (COMPAS) with PCV10 could not provide defini-
tive evidence on how the marketed formulation can im-
pact all-cause otitis media in a Latin American setting,
because they had a lower than expected number of
AOM cases [23].
Based on pneumococcal effectiveness and serotype dis-
tribution locally, PCV13 is cost-saving versus PCV10 in
regards to preventing pneumococcal disease due to allcauses, preventing mortality and obtaining LYG, which
leads to lower costs of care.
The main strength in this study is the local informa-
tion which helps to determine the epidemiological pa-
rameters for Colombia in regards to the diseases of
interest [10,11,13,15,17,19]. Likewise, the costs of the
medical treatments are based on a national third-party
payer, based on what really got paid to hospitals for the
care of patients. There was no underreporting of the
costs information (since it is the universe of the data
base of what was paid by the insurer). The adjustment of
the effectiveness of both vaccines based on the pneumo-
coccus serotypes circulating in Colombia between 2009
and 2013 permits an updated analysis. Finally, this study
includes information on the herd effect of PCV7 ob-
served in children [20], assuming that such effect is
similar for both vaccines.
The main weakness of this study is we do not have in-
formation from a head to head clinical trial between
PCV13 and PCV10. Similarly, results of the COMPAS [22]
study are difficult to compare because the average of follow
up was 23 months, compared to four and a half years of
the Northern California Kaiser Permanente Vaccine Study
[5]. It could affect the results of the first one trial because
the follow up was 31 months lesser than Kaiser Study, but
is the best information source available about PCV10 ef-
fectiveness. In the same direction, lack of inclusion of a
herd effect for children > 5 years of age and adults underes-
timates the full potential impact of the vaccines, in particu-
lar the additional benefit of PCV13, because serotypes 3,
6A and 19A cause pneumococcal disease in older adults.
Likewise, because the data on the prevalence of disease
was taken from official records, some underreporting
could have taken place, since the information depends on
whether or not the physician used the correct diagnosis
code. In the same way, the burden of diseases by pneumo-
nia could have been underestimated, because we just con-
sidered cases of radiologically-confirmed pneumonia.
This study did not evaluate aftermath generated by
any of the diseases, this is why the quality-adjusted life
years was not determined. It must be emphasized that in
terms of prevention of death due to all causes PCV13
was dominant over PCV10. Further, PCV13 prevented
more cases of disease, including meningitis, and there-
fore would be expected to provide greater reduction in
LYG and thus remain dominant in analysis.Conclusion
PCV13 and PCV10 are better cost-effectiveness alternatives
compared to no vaccination. PCV13 is dominant over
PCV10 since it prevents more deaths, generates more LYG
and the expected costs are lower (ICER PCV10 vs. PCV13:
US$ -417.53).
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